Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.28
-$0.07(-2.14%)
At close: 4:00 PM EST
$5.28
-$0.07(-2.14%)
Day’s Range― - ―
52-Week Range$2.92 - $6.30
Previous CloseN/A
Volume4.05K
Average Volume (3M)100.95K
Market Cap
$488.27M
Enterprise Value$372.58M
Total Cash (Recent Filing)$65.39M
Total Debt (Recent Filing)$62.42M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 11, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue4.59
Enterprise Value/Gross Profit6.82
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$7.50Price Target Upside42.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$93.40M
Bulls Say, Bears Say
Bulls Say
High Adjusted Gross MarginsSustained adjusted gross margins near 75% indicate strong unit economics for SOPHiA's analytics platform. High margins provide durable operating leverage as volume scales, enabling the company to invest in product development and sales while improving the path to adjusted EBITDA break-even as revenue grows.
Recurring Volume Growth And RetentionGrowing analysis volumes and a net dollar retention of 117% with sub-1% annualized churn show strong customer stickiness and upsell potential. This recurring, usage-linked revenue base supports predictable top-line expansion and long-term margin improvement as fixed costs are spread across rising throughput.
Strategic Partnerships And Biopharma TractionA Memorandum of Understanding with MSK to create a precision oncology JV is a structural boost: it combines clinical datasets and SOPHiA's analytics, accelerates product validation, and strengthens biopharma and CDx pathways. Such partnerships deepen moat and can drive higher‑value, stickier revenue streams over time.
Bears Say
Persistent Cash BurnSubstantial negative operating and free cash flow reduces financial flexibility and makes the business dependent on external funding or credit. Even with improvement versus prior years, ongoing cash consumption could force dilution, constrain strategic investments, or require tighter cost controls before sustained profitability.
Very Large Operating LossesDeep operating and net losses reflect a cost structure still far above current revenue scale. While gross margins are strong, high R&D, sales and G&A spending keep profitability distant; persistent losses raise execution risk that scale and operating discipline may not close the gap on schedule.
Rising Leverage And Balance Sheet PressureLeverage has increased materially, reducing financial flexibility and raising refinancing or covenant risk if cash burn continues. Moderate absolute debt paired with negative cash flow elevates interest and fixed obligations, limiting the company's ability to fund growth organically or absorb shocks like litigation and FX volatility.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.92 and its highest was $6.30 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $488.27M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.038.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.23.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 83,895,260 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (42.05% Upside)
$7.50 (42.05% Upside)
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $94.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
-140.63%
Trailing 12-Months
Asset Growth
7.00%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
SOPH Company Deck
SOPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a broadly constructive operational and commercial story: strong top-line growth (22% YoY), record analysis volumes, healthy unit economics (high adjusted gross margin ~75%), improved net dollar retention (117%), and accelerating application and biopharma momentum. Management also took targeted cost actions, expanded liquidity and reaffirmed full-year guidance. Offsetting these positives were higher cash burn, an increased operating loss, FX translation headwinds (Swiss franc up ~14% vs USD), ongoing litigation costs, and softness in Latin America. Growth is expected to be back-half weighted, which introduces execution risk for the year. Overall, the company shows strengthening fundamentals and a clear path toward profitability, but faces near-term cost, FX and legal headwinds that require monitoring.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$7.50
▲(42.05% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
9.15% Insiders
2.07% Mutual Funds
0.45% Other Institutional Investors
88.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---